Targinta develops first-in-class tumor-targeting antibodies and ADCs against the novel and patent protected cancer target integrin α10β1. Integrin α10β1 is a cell adhesion receptor that has been shown to be important for the ability of cancer cells to grow, proliferate and to metastasize. It is highly expressed in triple-negative breast cancer (TNBC) but not in normal breast tissue.

The new data presented at AACR includes target expression in different breast cancer cell lines and the demonstration of a positive correlation with TNBC aggressiveness. Further, it has been demonstrated that the integrin α10-antibody TARG10 reduces adhesion, migration, and proliferation of TNBC cells in vitro. This effect was associated with almost complete prevention of metastasis in a TNBC tumor model. In addition, data on pharmaceutical and pharmacokinetic properties are presented confirming excellent developability properties including pharmaceutical stability, low immunogenicity and a long terminal half-life in preclinical models.

“The new data on TARG10 gives strong support for the continued development of the candidate and for its potential to become a novel therapy for patients with triple-negative breast cancer. The observed effects on metastasis are truly impressive and a great validation of the mechanism of action of TARG10 and of our unique cancer target integrin α10β1 ", says Per Norlén, CEO at Targinta.

The poster will be presented by Katarzyna Masoumi, Project Director at Targinta AB, at 9 a.m. CDT (16.00 CEST) on April 12, 2022.
 
For further information please contact:
Per Norlén, CEO Targinta AB
Email: per.norlen@targinta.se
Phone: +46 46 275 65 00